10-Q: LataMed AI Corp. Q1 2026 Update: Strategic Shift to Healthcare Tech

LataMed AI Corp. reports a strategic pivot to AI-driven healthcare technology for Latin America, with no revenue in Q1 2026 and increased operating expenses.

Summary

• LataMed AI Corp. (formerly Catalyst Crew Technologies Corp.) has officially changed its name to LataMed AI Corp. as of April 28, 2026, reflecting a strategic shift.
• The company is transitioning its focus to developing artificial intelligence-enabled healthcare technology solutions and related services infrastructure, primarily targeting Latin America.
• During the first quarter of 2026, the company reported no revenue, consistent with the prior year's period.
• Operating expenses increased to $43,384 for the three months ended March 31, 2026, up from $15,967 in the same period of 2025, primarily due to higher professional fees.
• Net loss for the quarter ended March 31, 2026, was $52,813, compared to a net loss of $24,455 for the same period in 2025.
• The company has a working capital deficit of $683,673 as of March 31, 2026.
• Management has identified substantial doubt about the company's ability to continue as a going concern due to recurring net losses and accumulated deficits.
• The company plans to seek additional financing through a private equity offering to fund operations.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing negatively due to the widening net loss, lack of revenue, significant operating expense increase, and explicit concerns about the company's ability to continue as a going concern, despite a strategic pivot to a promising sector.

Positives

• Strategic pivot towards the growing AI-enabled healthcare technology sector.
• Establishment of a Venezuelan subsidiary to support operations and strategy in Latin America.
• Acquisition of proprietary healthcare technology assets and intellectual property related to AI-enabled healthcare analytics and services coordination.
• The company has designated a new Series C Voting Preferred Stock with significant voting rights, potentially strengthening governance and strategic decision-making.

Negatives

• No revenue generated in the first quarter of 2026, mirroring the previous year.
• Increased operating expenses by 171% to $43,384 due to higher professional fees.
• Net loss widened to $52,813 in Q1 2026 from $24,455 in Q1 2025.
• Significant working capital deficit of $683,673 as of March 31, 2026.
• Substantial doubt exists regarding the company's ability to continue as a going concern.
• Disclosure controls and procedures were found to be not effective due to limited internal resources and lack of multiple review levels.

Risks

• The company's ability to continue as a going concern is in doubt due to ongoing net losses and accumulated deficits.
• The company is entirely dependent on its ability to attract and receive funding from external sources, with no firm agreements in place.
• Failure to obtain sufficient funding will restrict the company's ability to grow and may require suspension of operations.
• Any additional equity financing may result in substantial dilution to existing stockholders.
• The company's strategic shift to healthcare technology involves significant execution risks and market adoption challenges.
• The company operates in a highly regulated industry (healthcare) which may present compliance challenges.
• The company has limited internal resources and a lack of effective disclosure controls and procedures, increasing the risk of financial misstatements or operational inefficiencies.

Future Outlook

The company is strategically pivoting to AI-enabled healthcare technology solutions for Latin America. Current activities focus on organizational development, operational structuring, technology evaluation, regulatory planning, and business development. The company plans to seek additional financing through a private equity offering to fund operations, but success is not assured.

Management Comments

• Management concluded that the company's financial disclosure controls and procedures were not effective due to limited internal resources and lack of multiple levels of transaction review.
• Management believes that the financial statements and other information presented are materially correct despite the control deficiencies.
• The company is entirely dependent on its ability to attract and receive funding from either the sale of securities or outside sources such as private investment or a strategic partner.
• The inability to obtain sufficient funding of our operations in the future will restrict our ability to grow and reduce our ability to continue to conduct business operations.

Industry Context

StockSavvy.ai notes that LataMed AI Corp.'s strategic shift into AI-enabled healthcare technology for Latin America aligns with broader industry trends of digital transformation in healthcare and the increasing adoption of AI for analytics and patient care. The focus on Latin America presents a unique market opportunity, though it also carries specific regulatory and operational challenges.

Comparison to Industry Standards

• The company's lack of revenue and net loss are common for early-stage technology companies, but the significant operating expenses relative to revenue are a concern.
• The company's disclosure control deficiencies are a red flag compared to established public companies that typically have robust internal controls.
• The reliance on external financing for survival is a standard challenge for many startups, but the explicit mention of 'substantial doubt about the Company's ability to continue as a going concern' highlights a higher level of risk than typically seen in more mature companies.

Management Changes

Corporate Governance

Legal Proceedings

• Management is currently not aware of any legal proceedings or claims that could have a material adverse effect on the business, financial condition, or operating results.

Related Party Transactions

• As of March 31, 2026, and December 31, 2025, the Company had notes due to its majority shareholder, Kevin Rodan Levy, totaling $88,042. These notes carry a 10% interest rate and are due upon demand.

Stakeholder Impact

• Shareholders: Potential for significant dilution from future equity financing; current financial performance raises going concern issues.
• Creditors: The company's working capital deficit and going concern status may impact its ability to meet obligations.
• Employees: Uncertainty regarding future operations due to funding dependence and potential restructuring.
• Management: Facing challenges in establishing effective internal controls and securing necessary funding.

Next Steps

• Secure additional financing through a private equity offering.
• Continue organizational development, operational structuring, technology evaluation, regulatory planning, and business development for the AI healthcare technology platform.
• Effectuate the name change to LataMed AI Corp. in the near future.
• Implement improvements to disclosure controls and procedures.

Key Dates

Recommendation

While the strategic pivot to AI healthcare technology is promising, the company's dire financial situation, lack of revenue, widening losses, and explicit going concern issues present significant risks. The company's survival is contingent on successful capital raises, which are uncertain. A 'hold' recommendation reflects the speculative nature of the investment, balancing the potential upside of the new strategy against the substantial immediate risks.

Keywords

LataMed AI Corp, Healthcare Technology, Artificial Intelligence, Latin America, Form 10-Q, Quarterly Report, Financial Statements, Going Concern, Net Loss, Operating Expenses, Asset Purchase Agreement, Startup, Biotech, Healthtech